|
1
|
Wanebo HJ and Vezeridis MP: Pancreatic
carcinoma in perspective. A continuing challenge. Cancer.
78:580–591. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and von Hoff DD:
Improvements in survival and clinical benefit with gemcitabine as
first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
3
|
Van Cutsem E, Verslype C and Grusenmeyer
PA: Lessons learned in the management of advanced pancreatic
cancer. J Clin Oncol. 25:1949–1952. 2007.PubMed/NCBI
|
|
4
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos
D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M and
Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine
alone in patients with advanced pancreatic cancer: a Phase III
trial of the National Cancer Institute of Canada Clinical Trials
Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar
|
|
5
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dancey J and Sausville EA: Issues and
progress with protein kinase inhibitors for cancer treatment. Nat
Rev Drug Discov. 2:296–313. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ueda S, Ogata S, Tsuda H, Kawarabayashi N,
Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K and Mochizuki
H: The correlation between cytoplasmic overexpression of epidermal
growth factor receptor and tumor aggressiveness: poor prognosis in
patients with pancreatic ductal adenocarcinoma. Pancreas. 29:e1–8.
2004. View Article : Google Scholar
|
|
8
|
Lee J, Jang K-T, Ki C-S, Lim T, Park YS,
Lim HY, Choi D-W, Kang WK, Park K and Park JO: Impact of epidermal
growth factor receptor (EGFR) kinase mutations, EGFR gene
amplifications and KRAS mutations on survival of pancreatic
adenocarcinoma. Cancer. 109:1561–1569. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takano T, Ohe Y, Sakamoto H, et al:
Epidermal growth factor receptor gene mutations and increased copy
numbers predict gefitinib sensitivity in patients with recurrent
non-small cell lung cancer. J Clin Oncol. 23:6829–6837. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Almoguera C, Shibata D, Forrester K,
Martin J, Arnheim N and Perucho M: Most human carcinomas of the
exocrine pancreas contain mutant c-K-ras genes. Cell. 53:549–554.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lohr M, Kloppel G, Maisonneuve P,
Lowenfels AB and Luttges J: Frequency of K-ras mutations in
pancreatic intraductal neoplasias associated with pancreatic ductal
adenocarcinoma and chronic pancreatitis: a meta-analysis.
Neoplasia. 7:17–23. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moore MJ, da Cunha Santos G, Kamel-Reid S,
Chin K, Tu D, Parulekar W, Ludkovski O, Squire J, Richardson F and
Tsao M: The relationship of K-ras mutations and EGFR gene copy
number to outcome in patients treated with erlotinib in the
National Cancer Institute of Canada Clinical Trials Group trial
study PA.3. Proc ASCO. 25:abs 45212007.
|
|
13
|
Dowell J, Minna JD and Kirkpatrick P:
Erlotinib hydrochloride. Nat Rev Drug Discov. 4:13–14. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morgan MA, Parsels LA, Kollar LE, Normolle
DP, Maybaum J and Lawrence TS: The combination of epidermal growth
factor receptor inhibitors with gemcitabine and radiation in
pancreatic cancer. Clin Cancer Res. 14:5142–5149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ng SS, Tsao MS, Nicklee T and Hedley DW:
Effects of the epidermal growth factor receptor inhibitor OSI-774,
Tarceva, on downstream signaling pathways and apoptosis in human
pancreatic adenocarcinoma. Mol Cancer Ther. 1:777–783.
2002.PubMed/NCBI
|
|
16
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koizumi F, Kanzawa F, Ueda Y, Koh Y,
Tsukiyama S, Taguchi F, Tamura T, Saijo N and Nishio K: Synergistic
interaction between the EGFR tyrosine kinase inhibitor gefitinib
(‘Iressa’) and the DNA topoisomerase I inhibitor CPT-11
(irinotecan) in human colorectal cancer cells. Int J Cancer.
108:464–472. 2004.
|
|
18
|
Chun PY, Feng FY, Scheurer AM, Davis MA,
Lawrence TS and Nyati MK: Synergistic effects of gemcitabine and
gefitinib in the treatment of head and neck carcinoma. Cancer Res.
66:981–988. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mendelsohn J and Baselga J: The EGF
receptor family as targets for cancer therapy. Oncogene.
19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morgan MA, Parsels LA, Parsels JD,
Mesiwala AK, Maybaum J and Lawrence TS: Role of checkpoint kinase 1
in preventing premature mitosis in response to gemcitabine. Cancer
Res. 65:6835–6842. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, McCullough KD, Franke TF and
Holbrook NJ: Epidermal growth factor receptor-dependent Akt
activation by oxidative stress enhances cell survival. J Biol Chem.
275:14624–14631. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyazaki Y, Hiraoka S, Tsutsui S, Kitamura
S, Shinomura Y and Matsuzawa Y: Epidermal growth factor receptor
mediates stress-induced expression of its ligands in rat gastric
epithelial cells. Gastroenterology. 120:108–116. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mahaffey CM, Davies AM, Lara PN Jr, Pryde
B, Holland W, Mack PC, Gumerlock PH and Gandara DR:
Schedule-dependent apoptosis in K-ras mutant non-small cell lung
cancer cell lines treated with docetaxel and erlotinib: rationale
for pharmacodynamic separation. Clin Lung Cancer. 8:548–553. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ling YH, Li T, Yuan Z, Haigentz M Jr,
Weber TK and Perez-Soler R: Erlotinib, an effective epidermal
growth factor receptor tyrosine kinase inhibitor, induces p27KIP1
up-regulation and nuclear translocation in association with cell
growth inhibition and G1/S phase arrest in human non-small cell
lung cancer cell lines. Mol Pharmacol. 72:248–258. 2007. View Article : Google Scholar
|
